| Autor: |
Almeida TB; Molecular Sciences, Astex Pharmaceuticals, Cambridge, UK., Panova S; Molecular Sciences, Astex Pharmaceuticals, Cambridge, UK., Walser R; Molecular Sciences, Astex Pharmaceuticals, Cambridge, UK. |
| Jazyk: |
angličtina |
| Zdroj: |
SLAS discovery : advancing life sciences R & D [SLAS Discov] 2021 Sep; Vol. 26 (8), pp. 1020-1028. Date of Electronic Publication: 2021 Apr 26. |
| DOI: |
10.1177/24725552211009782 |
| Abstrakt: |
Biophysical methods are widely employed in academia and the pharmaceutical industry to detect and quantify weak molecular interactions. Such methods find broad application in fragment-based drug discovery (FBDD). In an FBDD campaign, a suitable affinity determination method is key to advancing a project beyond the initial screening phase. Protein-observed (PO) nuclear magnetic resonance (NMR) finds widespread use due to its ability to sensitively detect very weak interactions at residue-level resolution. When there are issues precluding the use of PO-NMR, ligand-observed (LO) NMR reporter assays can be a useful alternative. Such assays can measure affinities in a similar range to PO-NMR while offering some distinct advantages, especially with regard to protein consumption and compound throughput. In this paper, we take a closer look at setting up such assays for routine use, with the aim of getting high-quality, accurate data and good throughput. We assess some of the key characteristics of these assays in the mathematical framework established for fluorescence polarization assays with which the readers may be more familiar. We also provide guidance on setting up such assays and compare their performance with other affinity determination methods that are commonly used in drug discovery. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
